{"id":2816,"date":"2026-08-24T22:54:21","date_gmt":"2026-08-24T22:54:21","guid":{"rendered":"https:\/\/officialcorepeptides.brandloom.net\/it\/?post_type=product&p=2816"},"modified":"2026-08-24T22:54:21","modified_gmt":"2026-08-24T22:54:21","slug":"buy-cjc-1295-dac-in-switzerland","status":"publish","type":"product","link":"https:\/\/officialcorepeptides.ch\/it\/product\/buy-cjc-1295-dac-in-switzerland\/","title":{"rendered":"CJC-1295 DAC (5MG)"},"content":{"rendered":"

What Is CJC-1295 DAC and Why Buy It for Research?<\/strong><\/h2>\n

Buy CJC-1295 DAC in Switzerland for research into growth hormone axis signaling, sustained GH release, and long-acting GHRH analog pharmacology. Specifically, CJC-1295 DAC (also known as DAC:GRF or CJC-1295 with Drug Affinity Complex) is a synthetic 30-amino acid peptide analog of growth hormone-releasing hormone (GHRH) that incorporates the first 29 residues of endogenous GHRH with a critical DAC extension. Structurally, it features the sequence Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH\u2082 with a maleimidopropionic acid DAC moiety attached to the lysine side chain at position 30.<\/p>\n

CJC-1295 DAC represents a significant advancement in peptide research design. The compound incorporates four strategic amino acid substitutions\u2014D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27\u2014that confer resistance to dipeptidyl peptidase-IV (DPP-IV) and other plasma proteases. Furthermore, the defining feature is the Drug Affinity Complex (DAC) moiety, which covalently binds to the free thiol group of cysteine-34 on endogenous serum albumin after administration, extending the plasma half-life to approximately 6-8 days. This albumin conjugation effectively circumvents the primary limitation of peptide drugs\u2014rapid in vivo degradation. Moreover, Core Peptides supplies CJC-1295 DAC as a lyophilized powder in a 5mg format exclusively for laboratory use. Therefore, researchers seeking to source this long-acting GHRH analog for their work will find it readily available when they buy CJC-1295 DAC in Switzerland.<\/p>\n

CJC-1295 DAC Research Overview: Buy CJC-1295 DAC in Switzerland for Long-Acting GHRH Studies<\/strong><\/h2>\n

Centrally, research into CJC-1295 DAC has focused on its function as a long-acting GHRH analog that provides sustained stimulation of the growth hormone axis. Endogenously, growth hormone-releasing hormone (GHRH) stimulates the pituitary gland to release growth hormone (GH), which in turn stimulates the liver to produce and secrete insulin-like growth factor-1 (IGF-1). However, therapeutic and research use of native GHRH is limited by its short duration of action, with a half-life of approximately 7 minutes due to rapid enzymatic degradation.<\/p>\n

CJC-1295 DAC overcomes this limitation through two key innovations. First, the tetrasubstituted amino acid backbone provides resistance to DPP-IV and other plasma proteases. Second, the DAC moiety covalently binds to circulating albumin after subcutaneous injection. This albumin conjugation extends the plasma half-life to approximately 6 to 8 days. A landmark 2006 Phase 1 randomized, placebo-controlled trial by Teichman and colleagues, published in the Journal of Clinical Endocrinology and Metabolism, reported that a single subcutaneous dose of CJC-1295 DAC (1\u201330 mcg\/kg) produced dose-dependent mean GH elevations of 2- to 10-fold and sustained IGF-1 elevations of 1.5- to 3-fold above baseline lasting 9 to 11 days. The estimated half-life in this study was 5.8-8.1 days. Accordingly, researchers who buy CJC-1295 DAC in Switzerland from Core Peptides can support their investigations into long-acting GHRH signaling, sustained GH and IGF-1 elevation, and growth hormone axis pharmacology.<\/p>\n

How Does CJC-1295 DAC Work in Research?<\/strong><\/h2>\n

Mechanistically, CJC-1295 DAC operates through a dual-action approach that combines receptor activation with sustained pharmacokinetic properties.<\/p>\n

GHRH Receptor Activation<\/strong><\/h3>\n

CJC-1295 DAC functions as a GHRH analog that binds to and activates the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs. This binding triggers a downstream signaling cascade via Gs\/cAMP\/PKA signaling that results in GH synthesis and secretion. Importantly, studies have demonstrated that pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295, preserving the physiologic secretory pattern even under sustained stimulation.<\/p>\n

Drug Affinity Complex (DAC) Technology<\/strong><\/h3>\n

The defining feature of CJC-1295 DAC is the Drug Affinity Complex moiety. This maleimidopropionic acid group, attached to the lysine side chain at position 30, is engineered to react selectively with the free thiol group of cysteine-34 on serum albumin. Following subcutaneous administration, this covalent binding to endogenous albumin extends the half-life to approximately 6 to 8 days, as established in the Teichman 2006 phase II trial.<\/p>\n

Sustained GH and IGF-1 Elevation<\/strong><\/h3>\n

This albumin conjugation provides prolonged exposure to elevated GH and IGF-1 levels. After a single injection of CJC-1295 DAC, researchers observed dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 days or more and in mean plasma IGF-I concentrations by 1.5- to 3-fold for 9-11 days. After multiple CJC-1295 doses, mean IGF-I levels remained above baseline for up to 28 days. This sustained action leads to increased circulating levels of GH and IGF-1 with infrequent dosing.<\/p>\n

Why Is CJC-1295 DAC Studied in Switzerland?<\/strong><\/h2>\n

Primarily, researchers study CJC-1295 DAC because it represents a well-characterized long-acting GHRH analog that enables investigation of sustained GH axis stimulation, somatotroph biology, and growth hormone pharmacology. In fact, this compound offers a focused tool for studying the molecular mechanisms underlying GH secretion, IGF-1 production, and growth hormone axis regulation.<\/p>\n

Research has demonstrated CJC-1295 DAC’s efficacy across multiple domains. In a study using GHRH knockout mice, long-term treatment with CJC-1295 DAC normalized growth parameters and body composition, and stimulated somatotroph cell proliferation and GH production in the anterior pituitary. Furthermore, the Teichman 2006 clinical trial established the pharmacokinetic and pharmacodynamic profile in healthy adults, demonstrating sustained, dose-dependent increases in GH and IGF-I levels with good tolerability. Preclinical and clinical studies have shown that CJC-1295 DAC can stimulate proliferation of somatotrophs and increase GH production. Ultimately, researchers who buy CJC-1295 DAC in Switzerland gain access to a comprehensive research tool for investigating long-acting GHRH signaling, somatotroph biology, and growth hormone axis pharmacology.<\/p>\n

CJC-1295 DAC Research Areas in Laboratory Studies<\/strong><\/h2>\n\n\n\n\n\n\n\n\n\n\n\n
Research Area<\/th>\nFocus<\/th>\nEvidence Level<\/th>\n<\/tr>\n<\/thead>\n
GH Axis Signaling<\/td>\nGHRH receptor activation, Gs\/cAMP\/PKA signaling, pulsatile GH secretion<\/td>\nMechanistic \/ Preclinical \/ Clinical<\/td>\n<\/tr>\n
Sustained GH Elevation<\/td>\nProlonged GH release, dose-dependent GH increases (2-10 fold), pharmacokinetics<\/td>\nClinical (Phase 1)<\/td>\n<\/tr>\n
IGF-1 Regulation<\/td>\nSustained IGF-1 elevation (1.5-3 fold), IGF-1 duration (9-11 days)<\/td>\nClinical (Phase 1)<\/td>\n<\/tr>\n
Somatotroph Proliferation<\/td>\nPituitary cell proliferation, GH production, somatotroph biology<\/td>\nPreclinical<\/td>\n<\/tr>\n
Albumin Conjugation<\/td>\nDAC technology, covalent albumin binding, extended half-life (6-8 days)<\/td>\nPharmacokinetic<\/td>\n<\/tr>\n
Growth and Body Composition<\/td>\nGrowth normalization, body composition, GHRH knockout models<\/td>\nPreclinical<\/td>\n<\/tr>\n
Long-Acting Peptide Design<\/td>\nDPP-IV resistance, tetrasubstituted analogs, peptide stability<\/td>\nMechanistic<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

CJC-1295 DAC Compared With Related Research Compounds<\/strong><\/h2>\n\n\n\n\n\n\n\n\n
Compound<\/th>\nResearch Focus<\/th>\nMechanism \/ Target<\/th>\nKey Difference<\/th>\n<\/tr>\n<\/thead>\n
CJC-1295 DAC<\/td>\nSustained GH\/IGF-1 elevation, long-acting GHRH signaling<\/td>\nGHRH-R activation + DAC albumin conjugation<\/td>\n30-amino acid peptide; half-life 6-8 days; sustained elevation<\/td>\n<\/tr>\n
CJC-1295 (No DAC \/ Mod GRF 1-29)<\/td>\nPulsatile GH release, GHRH signaling<\/td>\nGHRH-R activation only<\/td>\n29-amino acid peptide; half-life ~30 minutes; pulsatile release<\/td>\n<\/tr>\n
Tesamorelin<\/td>\nGHRH analog for lipodystrophy<\/td>\nGHRH-R activation<\/td>\nFDA-approved for HIV-associated lipodystrophy; shorter half-life<\/td>\n<\/tr>\n
Sermorelin<\/td>\nGHRH analog for GH deficiency<\/td>\nGHRH-R activation<\/td>\nShort half-life; requires frequent administration<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Comparatively, CJC-1295 DAC differs from other GHRH analogs in its extended pharmacokinetic profile. On the one hand, CJC-1295 without DAC (Mod GRF 1-29) has a half-life of approximately 30 minutes and mimics the natural, pulsatile release of GHRH. On the other hand, CJC-1295 DAC achieves a half-life of approximately 6 to 8 days through covalent albumin binding, providing sustained GH and IGF-1 elevation. In contrast, tesamorelin and sermorelin have shorter half-lives and require more frequent administration.<\/p>\n

Research Applications for CJC-1295 DAC in Switzerland<\/strong><\/h2>\n

Scientists have investigated CJC-1295 DAC across several research domains:<\/p>\n